Pharmaceutical Processing World

  • Home
  • Regulatory
    • Recalls
  • Pharmaceutical Processing
  • Facility
  • Supply Chain
  • Equipment and Materials
  • Contract Manufacturing
  • Resources
    • Voices
  • Advertise
  • SUBSCRIBE

Boehringer Ingelheim Finalizes Acquisition of Amgen’s Fremont Facility

By Pharmaceutical Processing | March 25, 2011

Today Boehringer Ingelheim formally acquired Amgen’s biopharmaceutical
development and manufacturing facility in Fremont,
California. This acquisition
involves leasing buildings, acquiring physical equipment and assuming
manufacturing processes done at the Fremont
site. The state-of-the-art facility currently employs more than 300 employees
and consists of more than 200,000 square feet for laboratories, manufacturing
and process development suitable for clinical and market supplies. The purchase
agreement was signed in January 2011. The companies agreed not to disclose
details of the purchase price.

“Presence in Fremont,
CA aligns with our growth
strategy in several ways,” said Simon Sturge, Corporate Senior Vice
President Biopharmaceuticals, Boehringer Ingelheim GmbH. “The strategic
decision to have a state–of-the-art contract manufacturing facility in the U.S.
Bay Area biotechnology cluster will give Boehringer Ingelheim a greater
opportunity to serve current and future customers.  In addition the
technological expertise present at Fremont
will complement our goal to further increase Boehringer Ingelheim’s world
leading position in the process development and manufacture of
Biopharmaceuticals.”  

As a fully integrated manufacturing site, the Fremont site complements
the existing capabilities and technology found across the existing Boehringer
Ingelheim biopharma network located in Biberach/Germany and Vienna/Austria.

Boehringer Ingelheim has been a contract manufacturer for
Amgen for ten years and will continue to support Amgen’s delivery of safe and
effective medicines to patients around the world. “We look forward to our
continued contract manufacturing partnership with Amgen,” said Simon
Sturge.

The Boehringer Ingelheim contract manufacturing portfolio
includes sixteen licensed biopharmaceuticals manufactured in globally licensed
multi-product facilities, a growing pipeline of New Biological Entities (NBEs),
and a growth strategy in the Contract Manufacturing Business (CMB). Boehringer
Ingelheim’s objective is to remain a leader in Contract Manufacturing as an
industry benchmark for operational excellence including technical expertise and
state-of-the-art technology.

 

Related Articles Read More >

This is the logo of Hikma.
Hikma to spend another $1B on US manufacturing, R&D
Sandoz Logo 2025
Sandoz breaks ground on biosimilar plant in Slovenia
Nymi Logo_2022 (1)
Nymi, Caliber partner on passwordless authentication for pharma manufacturing
Building a resilient pharma supply chain
“ppw
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest news, technologies, and developments in Pharmaceutical Processing.

DeviceTalks Tuesdays

DeviceTalks Tuesdays

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.
Pharmaceutical Processing World
  • Subscribe to our E-Newsletter
  • Contact Us
  • About Us
  • R&D World
  • Drug Delivery Business News
  • Drug Discovery & Development
  • DeviceTalks
  • MassDevice
  • Medical Design & Outsourcing
  • MEDICAL TUBING + EXTRUSION
  • Medical Design Sourcing
  • Medtech100 Index
  • R&D 100 Awards

Copyright © 2025 WTWH Media LLC. All Rights Reserved. The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media
Privacy Policy | Advertising | About Us

Search Pharmaceutical Processing World

  • Home
  • Regulatory
    • Recalls
  • Pharmaceutical Processing
  • Facility
  • Supply Chain
  • Equipment and Materials
  • Contract Manufacturing
  • Resources
    • Voices
  • Advertise
  • SUBSCRIBE